|The SPC Regulation before|
the CJEU got to it ...
|... and after|
|Worth fighting for|
Against this backdrop, it is unsurprising that events are organised at which the law on SPCs is examined and discussed. The SPC Blog's annual seminar is a good example, and many patent conferences contain sessions dedicated to them. However, the "big one" is C5's annual Pharmaceutical Patent Term Extensions Forum, a two-day event that is now in its 14th year. This year's version, subtitled "Maximising pharmaceutical patent lifecycles to foster innovation and growth", takes place at The Hotel Excelsior, Munich, from 22 to 23 June and is followed by a Masterclass on 24 June on how to draft solid pharma patent claims in light of the CJEU's rulings in Neurim, Medeva, Georgetown, Eli Lilly and Actavis v Sanofi. According to the organisers' blurb:
“Big Pharma” has reached a critical tipping point, due to the notable patent cliff which will occur this year. It is estimated that in 2015 $47.5 billion of lost sales will affect the industry overall. It is critical for pharmaceutical companies to capitalise on their R&D expenditure by obtaining Supplementary Protection Certificates in Europe, but there are also other legal and technical ways to maximise a patent's lifecycle in Europe and around the world.
This conference will examine the ways in which exclusivity on a patent can be extended for the longest term, such as re-patenting, data exclusivity, paediatric exclusivity and regulatory extensions. It will also provide you with implementable tools to maximise your patents’ lifecycle in those countries which don’t offer patent term extensions and will dig deeper into the challenges you face in critical markets such as China, India and Brazil.
Details of the programme and registration details can be found by clicking here. This Kat is pleased to inform readers that they are entitled to the benefit of a 10% discount on their registration fee if they quote the VIP KatCode “IPKAT10” when registering.